Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07037758 · ClinicalTrials.gov registry record · Phase 1

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

A Phase 1 study of Extensive-stage Small-cell Lung Cancer, sponsored by Amgen.

Recruiting
Registry status
Phase 1
Development phase
380
Enrollment target
17
Study locations

NCT07037758 is a Phase 1 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Amgen. The registered enrollment target is 380 participants, above the 160-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (138% higher). The trial reports 17 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07037758, a Phase 1 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Amgen.

RECRUITING
Registry status
Phase 1
Development phase
380 participants
Enrollment target
17
Study locations

Study Summary

The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB248 in combination with tarlatamab.

Conditions Studied

Extensive-stage Small-cell Lung Cancer

Interventions

  • DRUG Tarlatamab
  • DRUG AB248

Study Locations (17)

Other

  • Chungbuk National University Hospital - Cheongju Chungbuk
  • Seoul National University Bundang Hospital - Seongnam-si, Gyeonggi-do
  • Severance Hospital Yonsei University Health System - Seoul
  • Adana Sehir Egitim ve Arastirma Hastanesi - Adana
  • Hacettepe Universitesi Tip Fakultesi Hastanesi - Ankara
  • Ankara Bilkent Sehir Hastanesi - Ankara

Pennsylvania

  • Sidney Kimmel Cancer Center - Philadelphia
  • Allegheny General Hospital - Pittsburgh

California

  • University of Southern California, Norris Comprehensive Cancer Center - Los Angeles

Florida

  • Moffitt Cancer Center - Tampa

Georgia

  • Emory University - Atlanta

Kentucky

  • Norton Cancer Institute - Downtown - Louisville

Massachusetts

  • Dana-Farber Cancer Institute - Boston

Missouri

  • Siteman Cancer Center - St Louis

Trial Details

FieldValue
Enrollment Target 380 participants
Start Date 2025-09-16
Est. Completion 2031-01-18
Phase Phase 1

Sponsor

Amgen

558 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07037758

The ClinicalTrials.gov registry entry for NCT07037758 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 160-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (138% higher). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Tarlatamab is the first listed.

NCT07037758 reports 17 study locations spanning 11 distinct geographic areas - top geographies include Other, Pennsylvania, California.

Frequently Asked Questions

What is clinical trial NCT07037758 about?

NCT07037758 is a clinical study titled "A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)". The primary objective for dose exploration and dose expansion is to evaluate the safety and tolerability of tarlatamab in combination with AB248. The primary objective for dose exploration only is to determine the recommended dose for expansion and/or maximum tolerated combination dose (MTCD) of AB...

What is the current status of trial NCT07037758?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 380 participants. The study started on 2025-09-16. Estimated completion is 2031-01-18.

What conditions does trial NCT07037758 study?

This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.

What interventions are being tested in trial NCT07037758?

The interventions under investigation include: Tarlatamab (DRUG), AB248 (DRUG).

Who is sponsoring clinical trial NCT07037758?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07037758 being conducted?

This trial has 17 study locations across California, Florida, Georgia, Kentucky, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Extensive-stage Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Extensive-stage Small-cell Lung Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.